C07D 239/91
With aryl or aralkyl radicals attached in position 2 or 3
Official title: with aryl or aralkyl radicals attached in position 2 or 3
C07D239/91 (With aryl or aralkyl radicals attached in position 2 or 3) appears on 323 US grants and 321 published applications in this corpus.
Search patents in C07D- Granted patents
- 323
- Published applications
- 321
- Assignees
- 223
- Inventors
- 1,132
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 3 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 4 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 5 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 5 | 0 |
| 1994 | 8 | 0 |
| 1995 | 9 | 0 |
| 1996 | 4 | 0 |
| 1997 | 5 | 0 |
| 1998 | 13 | 0 |
| 1999 | 7 | 0 |
| 2000 | 6 | 0 |
| 2001 | 7 | 0 |
| 2002 | 3 | 3 |
| 2003 | 7 | 12 |
| 2004 | 5 | 25 |
| 2005 | 7 | 15 |
| 2006 | 11 | 18 |
| 2007 | 12 | 17 |
| 2008 | 7 | 19 |
| 2009 | 6 | 11 |
| 2010 | 16 | 16 |
| 2011 | 14 | 13 |
| 2012 | 11 | 18 |
| 2013 | 11 | 18 |
| 2014 | 17 | 19 |
| 2015 | 22 | 20 |
| 2016 | 14 | 19 |
| 2017 | 17 | 9 |
| 2018 | 13 | 8 |
| 2019 | 7 | 10 |
| 2020 | 7 | 9 |
| 2021 | 5 | 5 |
| 2022 | 4 | 4 |
| 2023 | 3 | 12 |
| 2024 | 0 | 7 |
| 2025 | 4 | 5 |
| 2026 | 4 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Histone deacetylase inhibitors26 May 2026US 12,637,433 B2The University of Queensland
- Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof14 Apr 2026US 12,600,702 B2Bausch + Lomb Ireland Limited
- Quinazolinone derivatives10 Mar 2026US 12,570,615 B2Hoffmann-La Roche Inc.
- Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof20 Jan 2026US 12,528,777 B2Council of Scientific and Industrial Research
- Heteroaryl compounds for the treatment of pain23 Dec 2025US 12,503,439 B2Vertex Pharmaceuticals Incorporated
- 3-phenylquinazolinones as novel anti-cancer therapy23 Jul 2026US 2026/0209218 A1Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- Flavones, quinolinones, quinazolinones, and aurones, and uses in ck2-mediated diseases16 Jul 2026US 2026/0199350 A1The Salk Institute for Biological Studies
- Hsd17b13 inhibitors and uses thereof9 Jul 2026US 2026/0193218 A1Inipharm, Inc.
- Translocator protein ligands and inflammatory diseases25 Jun 2026US 2026/0174761 A1Technion Research & Development Foundation Limited
- Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof25 Jun 2026US 2026/0176239 A1Bausch + Lomb Ireland Limited
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta180US 7,932,260 B2ICOS Corporation · 2011
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997